The concomitant use of VYVANSE and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of VYVANSE compared to the use of the drug alone and increase the risk of serotonin syndrome.VYVANSE is not for weight loss. It is not known if VYVANSE is safe and effective for the treatment of obesity.or problems while taking